Prostate Cancer Drug Combo Cuts Metastasis Risk, Gains Stay Modest

Adding a second hormone drug before and after prostate surgery cut the relative risk of metastasis or death by 20 percent in a 2,109-patient phase 3 trial. In plain terms, five-year metastasis-free survival rose from 73.5 percent to 78.2 percent. That is a gap of fewer than five percentage points, and overall survival data are not yet mature.

The PROTEUS trial is being called a watershed by several leading oncologists, and the relative-risk numbers are genuinely strong. The absolute gains, and what is still missing from the readout, argue for a narrower verdict than the headlines suggest.

How the PROTEUS Regimen Works

PROTEUS tested a perioperative approach, meaning treatment wrapped around the operation on both sides. Patients with high-risk localized or locally advanced prostate cancer received six months of therapy before a radical prostatectomy and six months after it.

Every patient got androgen deprivation therapy (ADT, the standard treatment that shuts down testosterone, the fuel for prostate tumors). Half were randomly assigned to add apalutamide, sold by Johnson & Johnson as ERLEADA, a drug that blocks the androgen receptor more completely. The other half received ADT plus a placebo. The study was double-blind, so neither patients nor doctors knew who got what.

This is a meaningful break from current practice. For high-risk patients who choose surgery, hormone therapy has not been a routine companion to the operation. The trial asked whether bolting a year of intensified hormonal treatment onto the procedure changes the long-term picture. After a median follow-up of 61.7 months, the answer was yes, with caveats. You can read the full PROTEUS trial results from Johnson & Johnson for the complete endpoint list.

The Gap Between Relative and Absolute Benefit

The trial met both primary endpoints, and the relative-risk figures are the ones being quoted everywhere. The reduction in risk of metastasis or death carried a hazard ratio of 0.80. The pathologic response numbers look even more dramatic as a ratio: patients on the combination were about nine times more likely to have little or no cancer left at surgery.

Read in absolute terms, the same data look more measured. A pathologic complete response or minimal residual disease showed up in 8.9 percent of the combination group versus 1.0 percent of the ADT-only group. Nine times more is true; it is also nine times a small number. The five-point metastasis-free survival gap is the figure a patient would actually feel.

The time-to-next-therapy figure is the most concrete win for patients. Pushing the next round of treatment out by nearly 33 months means years before a man faces radiation, more drugs, or the side effects that come with them. That endpoint, more than the survival curve, is what supporters point to. The detailed hazard ratios and confidence intervals appear in the full endpoint data released at ASCO.

Why Some Oncologists Call It a Watershed

The enthusiasm is not hard to understand. Prostate cancer surgery has changed slowly for decades, and PROTEUS is the first phase 3 study to show that wrapping intensified hormone therapy around the operation lowers the odds of cancer spreading.

Emmanuel Antonarakis, a genitourinary medical oncologist at the University of Minnesota, called the result a “watershed moment” in prostate cancer in a New England Journal of Medicine editorial. The trial’s senior author went further on what it could mean for daily practice.

The outcomes of this trial have the potential to reshape the standard of care for our patients with high-risk prostate cancer.

That was Adam Kibel, chair of the department of urology at Mass General Brigham and the study’s senior author. Mary-Ellen Taplin, a medical oncologist at Dana-Farber Cancer Institute and the principal investigator, framed it as catching up to other tumor types, where combining drugs with surgery is already routine. Their case rests on a familiar logic in cancer medicine: hit the disease hard and early, before it has a chance to seed elsewhere. Dana-Farber’s summary of the perioperative findings lays out the investigators’ reasoning.

The Side-Effect Burden of Doubling Up

Intensifying hormone therapy comes with a cost, and PROTEUS measured it. A year of androgen blockade hits quality of life in ways high-risk patients weigh carefully against a five-point survival edge.

• 63.4 percent of combination-arm patients reported hot flushes.
• 50.2 percent experienced urinary incontinence.
• 41.6 percent reported erectile dysfunction.
• Grade 3 or 4 adverse events hit 39.6 percent of the apalutamide group versus 31.0 percent on ADT alone.

Discontinuations because of side effects ran at 7.4 percent in the combination arm, nearly three times the 2.7 percent seen with hormone therapy alone. Skin rash was more common with the added drug, and death rates were similar between the two groups. Testosterone took a median of 8.1 months to recover to adequate levels after treatment ended, a reminder that the hormonal hit lingers well past the final dose.

None of this is unusual for androgen blockade. The point is that the extra benefit and the extra toxicity travel together, and a man choosing this path is signing up for both.

Surgery Versus Radiation Plus Hormones

PROTEUS lands in a field that already has a well-tested rival. High-risk patients who do not want surgery are usually offered radiation therapy paired with hormone therapy, a combination backed by long-running trials and survival data.

That matters for how far the new findings travel. The trial improves the surgical route specifically; it does not pit surgery-plus-hormones against radiation-plus-hormones head to head. A patient weighing options still has to compare a freshly intensified surgical path against an established radiation path that already folds hormone therapy into the plan.

Apalutamide is not yet approved for use around surgery. It currently carries approvals for non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer, both later-stage settings. Using it before and after a prostatectomy would be a new indication that regulators have not signed off on. The trial design that set up this question is detailed in the original PROTEUS study protocol published in the Journal of Clinical Oncology.

What Stands Between the Data and a New Standard

For all the watershed talk, several things have to fall into place before this regimen becomes routine. The strongest argument for caution is what the trial has not yet shown.

1. Overall survival has to mature. Metastasis-free survival is a strong stand-in, but it is not the same as showing men live longer. That data point is still developing, and it is the one regulators and guideline writers care about most.
2. Regulators have to approve the new use. Apalutamide works in this setting in the trial, but a perioperative indication requires a fresh regulatory review before doctors can prescribe it that way as standard.
3. Guideline bodies have to update. Major cancer guidelines move on the full published evidence, weighing the modest absolute gains against the real toxicity load before naming a new standard of care.

The benefit is real and the time-to-next-treatment gain is the kind of result that changes conversations in the clinic. Whether it changes the playbook depends on the next readout. If the overall survival curve eventually separates the way the metastasis data did, the watershed label earns itself and a new standard follows. If it stays flat, this remains a strong option for a narrow slice of high-risk patients willing to trade a year of harsher side effects for a few points of margin.

Frequently Asked Questions

What Is the PROTEUS Trial?

PROTEUS is a phase 3, randomized, double-blind, placebo-controlled study of 2,109 patients with high-risk localized or locally advanced prostate cancer. It tested apalutamide plus androgen deprivation therapy, given for six months before and six months after radical prostatectomy, against hormone therapy alone.

How Much Did the Treatment Reduce the Risk of Metastasis?

The combination cut the relative risk of metastasis or death by 20 percent, with a hazard ratio of 0.80. In absolute terms, five-year metastasis-free survival was 78.2 percent with the combination versus 73.5 percent with hormone therapy alone.

Does PROTEUS Show Patients Live Longer?

Not yet. The trial met its endpoints on metastasis-free survival and pathologic response, but overall survival data are still maturing. That missing piece is why some experts urge caution before calling the regimen a new standard of care.

What Are the Side Effects of the Combination?

Common side effects included hot flushes (63.4 percent), urinary incontinence (50.2 percent), and erectile dysfunction (41.6 percent). Grade 3 or 4 adverse events occurred in 39.6 percent of the combination group versus 31.0 percent on hormone therapy alone, and discontinuations from side effects were higher with the added drug.

Is Apalutamide Approved for Use Around Surgery?

No. Apalutamide is currently approved for non-metastatic castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer. Using it before and after a prostatectomy would require a new regulatory approval that has not yet been granted.

How Does This Compare to Radiation Plus Hormone Therapy?

PROTEUS improves the surgical route by adding intensified hormone therapy around the operation. It did not directly compare surgery against radiation combined with hormone therapy, which remains a well-established option for high-risk patients who do not choose surgery.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Prostate cancer treatment decisions carry significant risks and benefits that vary by individual; patients should consult a qualified oncologist or urologist before making any treatment choice. Figures and trial data are accurate as of publication.